Navigation Links
Oncolytics Biotech Inc. Announces Publication of Research on Immune Response to REOLYSIN(R) during a Phase I Clinical Trial
Date:3/17/2008

CALGARY, March 17 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ('Oncolytics') reported today that Dr. Kevin Harrington and his research group at The Institute of Cancer Research, London, U.K. published the results of their work characterizing immune system responses to administration of intravenous REOLYSIN(R) in a Phase I clinical trial. The paper, entitled "Characterization of the Adaptive and Innate Immune Response to Intravenous Oncolytic Reovirus (Dearing Type 3) during a Phase I Clinical Trial" appears online in the March 6, 2008 issue of Gene Therapy.

"This important work further defines the relationship between viral therapy and human immune response, and supports the development of our ongoing Phase II clinical trial program," said Dr. Brad Thompson, President and CEO of Oncolytics.

The investigators conducted a detailed analysis of the immune effects of intravenous viral therapy by collecting and analyzing immune response to the presence of the virus. The results suggest that reovirus may stimulate the immune system to mount a dynamic immune response to the presence of virus, increasing the potential to significantly enhance the efficacy of oncolytic virotherapy. About a third of those patients also showed increases in NK (natural killer) cells following therapy. The data support the development of interventions aimed at blunting the patient's immune response, although preclinical data also suggest that maintaining a baseline level is necessary to restrict systemic spread/toxicity of the virus.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information abo
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at AACR Annual Meeting
2. Media Advisory - Oncolytics Biotech Inc. to Present at BioSquare 2008
3. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
4. Media Advisory - Oncolytics Biotech Inc. to Present at Bio CEO & Investor Conference
5. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Radiation Therapy
6. Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
7. Oncolytics Biotech Inc. Announces Issuance of 8th Canadian Patent
8. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Cyclophosphamide Treatment
9. Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R)
10. Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)... Inverness Medical Innovations, Inc. (NYSE: IMA ), a ... health at home through the merger of rapid diagnostics and ... on its Series B Convertible Perpetual Preferred Stock ( IMA-PB). ... stock in an amount per share equal to the quotient ...
(Date:12/2/2009)... announces that a new market research report ... Neurostimulation - A Global Market Perspective ... world neurostimulation market stands enthused by the ... resultant rise in age-related diseases such as, ...
(Date:12/2/2009)... Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today ... and dosimetry trial of Cotara® in patients with relapsed ... Cotara is a targeted monoclonal antibody linked to ... for GBM. Cotara specifically targets cells at the ...
(Date:12/2/2009)... December 2 Gamida Cell announced today,a feasibility ... of a gene therapy product which combines technology ... product may have potential to,treat inherited anemias such ... Gamida Cell is developing a series of technologies ...
Breaking Biology Technology:Reportlinker Adds Neurostimulation - A Global Market Perspective 2Reportlinker Adds Neurostimulation - A Global Market Perspective 3Reportlinker Adds Neurostimulation - A Global Market Perspective 4Reportlinker Adds Neurostimulation - A Global Market Perspective 5Reportlinker Adds Neurostimulation - A Global Market Perspective 6Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 3
... Although Madison has made a deal with Georgia-based Cellnet ... not be an overnight event. Certain areas will be initially ... Square expected to be approved by the City Council in ... of Madison has taken an active role in brokering Cellnets ...
... At Third Wave Technologies, former vice president Kevin Conroy ... Puisis, who was CEO since mid-2004 and previously held other ... to Third Wave and stayed for a specific purpose," Puisis ... an upgraded, highly-skilled management team in place, that purpose has ...
... Third Wave Technologies ' compensation in a patent lawsuit ... legal fees. Stratagene is proceeding with its appeal. , ... found that Stratagene willfully infringed on two patents covering ... million. , ,Third Wave uses the technology in its ...
Other Biology Technology:Madison wireless deal goes forward with Cellnet 2
(Date:12/3/2009)... Now in its 32nd year, the CTRC-AACR San ... in breast cancer science and world leaders from industry ... , This year, more than 8,500 scientists and ... Convention Center in San Antonio from Dec. 9-13, 2009. ...
(Date:12/3/2009)... the design of the upcoming forest deal at Copenhagen in ... at the University of Leeds. , Writing today in ... 50% of the carbon credit payments to be agreed at ... should be made to forest dwellers directly, and their property ...
(Date:12/2/2009)... an increased risk of developing lung cancer in adulthood, even ... are published in Cancer Epidemiology, Biomarkers & Prevention , ... part of a special tobacco focus in the December issue. ... be diagnosed with lung cancer; more than 159,000 will die ...
Breaking Biology News(10 mins):CTRC-AACR San Antonio Breast Cancer Symposium continues to expand 2Forest deal at Copenhagen must avoid creating 'carbon refugees' 2Secondhand smoke exposure in childhood increases lung cancer risk later in life 2Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 4703 1Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 4703 2Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 4703 3Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 4703 4Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 4703 5Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 4703 6Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 4703 7Cord Blood America Leases Las Vegas Building for Its Own Stem Cell Laboratory 51174 1Cord Blood America Leases Las Vegas Building for Its Own Stem Cell Laboratory 51174 2Cord Blood America Leases Las Vegas Building for Its Own Stem Cell Laboratory 51174 3Big Cuts in Family Budgets Usually Means Insurance Gets the Ax 51171 1Big Cuts in Family Budgets Usually Means Insurance Gets the Ax 51171 2
... (IL-2), an immune-boosting drug used experimentally in HIV therapy, ... system T cells in some HIV-positive people who respond ... of Health (NIH) Clinical Center and the National Institute ... NIH. A report describing the study, led by the ...
... heart attack and unstable angina patients placed on beta-blocker ... to a study by researchers at Washington University School ... Heart Institute in Kansas City. The study appears in ... the American Medical Association. , "In our investigation of ...
... of 72 cases of monkeypox in the United States ... fatality, even though the disease usually kills 10 percent ... patients die? New research from Saint Louis University Health ... answer. , In this month's issue of Virology, researcher ...
Other Biology News:HIV Therapy Greatly Extends Life of Key T Cells, Scientists Find 2HIV Therapy Greatly Extends Life of Key T Cells, Scientists Find 3Survival of heart patients on beta-blockers varies greatly with genetic variation 2Survival of heart patients on beta-blockers varies greatly with genetic variation 3Survival of heart patients on beta-blockers varies greatly with genetic variation 4Monkeypox mystery: New research may explain why 2003 outbreak in the US wasn't deadly 2
Human peripheral blood PBMCs, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood PBMC and T Cells...
Human peripheral blood CD19+ B cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
Umbilical cord blood mononuclear cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood MNCs and T Cells...
Human plasmacytoid dendritic cells, BDCA-4+, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Dendritic Cells and EPCs...
Biology Products: